Effect of mononuclear cells versus pioglitazone on streptozotocin-induced diabetic nephropathy in rats

Pharmacological Reports

Volumn 64, Issue 5, 2012, Pages 1223-1233

  Masoad, Riham E ^a   Ewais, Mohamed M S ^a   Tawfik, Mona K ^a   Abd El All, Hwayda S ^a  

^a Suez Canal University Faculty of Medicine   (Egypt)

Author keywords

Diabetic nephropathy; Laminin; MNCs; Pioglitazone; Type 1 diabetes

Indexed keywords

LAMININ; PIOGLITAZONE;

ANIMAL CELL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BIOACCUMULATION; CELL THERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; EXTRACELLULAR MATRIX; GLYCEMIC CONTROL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY STRUCTURE; MALE; MONONUCLEAR CELL; NONHUMAN; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; TREATMENT OUTCOME;

EID: 84873715620     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70918-0     Document Type: Article

References (57)

1. Aaltonen P, Luimula P, Tuula P, Ahola H, Palmén T, Holthöfer H: Changes in the expression of nephrin gene and protein in experimental diabetic nephropathy. Lab Invest, 2001, 81, 1185-1190. (Pubitemid 32911967)
2. Aumaille M: A simplified laminin nomenclature. Matrix Biol, 2005, 24, 326-332.
3. Bao Y, Jia R, Yuan J, Li J: Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its downstream-signaling pathways. Pharmacol J, 2007, 80, 57-64. (Pubitemid 47013368)
4. Brosius F: New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev Endocr Metab Disord, 2008, 9, 245-254.
5. Carvalho E, Ferreira L: Experimental models of induction of diabetes mellitus in rats. Acta Cir Bras, 2003, 18, 60-64.
6. Detata V, Novelli M, Bombara M: Determination of glycated hemoglobins in the rat: comparison between two different chromatographic methods and application in experimental diabetology. Res Exp Med (Berl), 1996, 196, 9-16. (Pubitemid 26064264)
7. Du J, Wang L, Liu L, Fan Q, Yao L, Cui Y, Kang P et al.: IFN-γ suppresses the high glucose-induced increase in TGF-β1 and CTGF synthesis in mesangial cells. Pharmacol Rep, 2011, 63, 1137-1144.
8. Earle K: Variation of progression of diabetic nephropathy according to racial origin. Nephrol Dial Transplant, 2007, 16, 286-290.
9. Ende N, Chen R, Reddi A: Transplantation of human umbilical cord blood cells improves glycemia and glomerular hypertrophy in type 2 diabetic mice. Biochem Biophys Res Commun, 2004, 321, 168-171. (Pubitemid 39055619)
10. Ende N, Chen R, Reddi A: Effect of human umbilical cord blood cells on glycemia and insulitis in type 1 diabetic mice. Biochem Biophys Res Commun, 2004, 325, 665-669. (Pubitemid 39489894)
11. Erensoy N, Yilmazer S, Öztürk M, Tunçdemir M, Uysal O, Hatemi H: Effects of ACE inhibition on the expression of type IV collagen and laminin in renal glomeruli in experimental diabetes. Acta Histochem, 2004, 106, 279-287. (Pubitemid 39179948)
12. Feige J, Gelman L, Michalik L, Desvergne B, Wahli W: From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res, 2006, 45, 120-159. (Pubitemid 43248732)
13. Feng-qin D, Hong L, Wei-min C, Jun T, Qun L, Yu R: Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats. Chin Med J, 2004, 117, 1040-1044.
14. rd edn. Lippincott Williams & Wilkins, Philadelphia, 2004.
15. Gang J, Young S, Sang Y, Mi H: pioglitazone attenuates diabetin nephropathy through anti-inflamatory mechanism. Nephrol Dial Transplant, 2007, 23, 750-760.
16. Gellman D, Pirani C, Soothill G, Muethrcke R, Kark R: Diabetic nephropathy: clinical and pathologic studies based on renal biopsy. Med J, 1959, 38, 312-317.
17. Gumieniczek A: Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits. Life Sci, 2003, 74, 553-562.
18. Hirasawa Y, Matsui Y, Yamane K, Yabuki SY, Kawasaki Y, Toyoshi T, Kyuki K, et al.: Pioglitazone improves obesity type diabetic nephropathy: relation to the mitigation of renal oxidative reaction. Exp Anim, 2008, 57, 423-432.
19. Hussain M, Theise N: Stem-cell therapy for diabetes mellitus. Lancet, 2004, 364, 203-205.
20. Iglesias P. Díez J: Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur J Endocrinol, 2006, 154, 613-621. (Pubitemid 43810845)
21. Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T, Kikkawa R: Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes, 2000, 49, 1022-1032. (Pubitemid 30349426)
22. Jaatinen T, Laine J: Isolation of mononuclear cells from human cord blood by Ficoll Paque density gradient. Curr Prot Stem Cell Biol, 2007, 2A.1.
23. Kakadiya J, Brambhatt J, Shah N: Renoprotective activity of pioglitazone on ischemia/reperfusion induced renal damage in diabetic rats. Rec Res Sci Tech, 2010, 2, 92-97.
24. Kan C, Wu C, Zhang M, Wang L: Pioglitazone renal cortex of diabetic vascular endothelial growth factor expression. Diabetes, 2011, 48, 2229-2239.
25. Katavetin P, Eiam-Ong S, Suwanwalaikorn S: Pioglitazone reduces urinary protein and urinary transforming growth factor-β excretion in patients with type 2 diabetes and overt nephropathy. J Med Assoc Thai, 2006, 89, 170-177. (Pubitemid 44743406)
26. Ko GJ, Kang YS, Han SY, Lee MH, Song HK, Han KH, Kim HK et al.: Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant, 2008, 23, 2750-2760.
27. Koblas T, Harman S, Saudek F: The application of umbilical cord blood in treatment of diabetes mellitus. Rev Diabetic Stud, 2005, 2, 228-234.
28. Kuhad A, Chopra K: Attenuation of diabetic nephropathy by tocotrienol: involvement of NF-κB signaling pathway. Life Sci, 2009, 84, 296-301.
29. Lee G, Olson P, Hevener A: PPARδ regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA, 2006, 103, 3444-3449. (Pubitemid 43346488)
30. Lee R, Seo M, Reger R, Spees J, Pulin A, Prockop D: Multipotent stromal cells promote repair of pancreatic and renal glomeruli in diabetic NOD/SICD mice. Proc Natl Acad Sci USA, 2007, 103, 17438-17443. (Pubitemid 44788987)
31. Li J, Kwak SJ, Jung DS, Kim J, Yoo T, Ryu D: Podocyte biology in diabetic nephropathy. Kidney Int, 2007, 72, S36-S42. (Pubitemid 47172559)
32. Lim J, Jang J, Kim J, Moon S, Lee C, Lee K: Human umbilical cord blood mononuclear cell transplantation in rats with intrinsic sphincter deficiency. J Korean Med Sci, 2010, 25, 663-670.
33. Michalik L, Auwerx J, Berger J, Chatterjee V, Wahli W: International union of pharmacology. Peroxisome proliferator-activated receptors. Pharmacol Rev, 2006, 58, 726-741.
34. Mizutani A, Okajima K, Uchiba M, Noguchi T: Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood, 2000, 95, 3781-3787. (Pubitemid 30412850)
35. Neil H, Kyle C, Annette M, Thomas E: Cord blood in regenerative medicine: do we need immune suppression. J Transl Med, 2007, 26, 5-8.
36. Ende N, Ruifeng Chen R, Reddi AS: Transplantation of human umbilical cord blood cells improves glycemia and glomerular hypertrophy in type 2 diabetic mice. Biochem Biophys Res Commu, 2004, 321, 168-171. (Pubitemid 39055619)
37. Ohga S, Shikata K, Yozai K: Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-κB activation. Am J Physiol Renal Physiol, 2007, 292, F1141-F1150.
38. Okada T, Wada J, Hida K, Eguchi J, Hashimoto I, Baba M, Yasuhara A et al.: Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes, 2006, 55, 1666-1677.
39. Parker J: Can stem cell transplant treat diabetes and kidney disease? Stem Cells J, 2011, 29, 38-42.
40. Peterson JC, Adler S, Burkart J: Blood pressure control, proteinuria and the progression of renal disease: the modification of diet in renal disease study. Ann Int Med, 1995, 123,754-762.
41. Sarafidis PA, Lasaridis AN, Nilsson PM, Pagkalos EM, Hitoglou-Makedou AD, Pliakos A: The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Am J Hypertens, 2005, 18, 227-234. (Pubitemid 40332553)
42. Schaeffer V, Hansen K, Morris D, Abrass C: Reduction in laminin β2 mRNA translation is responsible for impaired IGFBP-5-mediated mesangial cell migration in the presence of high glucose. Am J Physiol Renal Physiol, 2010, 298, F314-F322.
43. Sevensson M, Eriksson J, Dahlquist G: Early glycemic control, age at onset, and development of microvascular complications in childhood-onset type 1 diabetes. Diabetes Care, 2004, 27, 955-962. (Pubitemid 38420221)
44. Taneda S, Jeffery W, Pippin B: Amelioration of diabetic nephropathy in SPARC-null mice. J Am Soc Nephrol, 2003, 14, 968-980. (Pubitemid 36359278)
45. Thallas-Bonke V, Lindschau C, Rizkalla B, Bach LA, Boner G, Meier M, Haller H et al.: Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-α-dependent pathway. Diabetes, 2004, 53, 2921-2930. (Pubitemid 39425918)
46. Toblli J, Cao G, Giani J, Angerosa M, Dominici F, Gonzalez-Cadavid N: Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the improvement of markers of cell turnover, tubular and endothelial integrity, and angiogenesis. Kidney Blood Press Res, 2011, 34, 20-33.
47. Trinder P: Determination of blood glucose using 4-aminophenazone as oxygen acceptor. J Clin Pathol, 1969, 222, 46-50.
48. Tuch B: Stem cells - a clinical update. Aust Family Phys, 2006, 35, 719-721.
49. Vijay S, Mishra M, Kumar H, Tripathi K: Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. Acta Diabetol, 2006, 46, 27-33.
50. Volarevicn V, Arsenijevic E, Miodrag L: Concise review: Mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells J, 2011, 29, 5-10.
51. Wang X, Jiang T, Levi M: Nuclear hormone receptors in diabetic nephropathy. Nature Rev Nephrol, 2010, 6, 342-351.
52. Tse W, Laughlin M: Umbilical cord blood transplantation: A new alternative option. Hematol J, 2005, 377-383.
53. Wobus A, Boheler K: Embryonic stem cells: prospects for developmental biology and cell therapy. Physiol Rev, 2005, 85, 635-678. (Pubitemid 40404638)
54. Xu X, Chen P, Zheng Q, Wang Y, Chen W: Effect of pioglitazone on diabetic nephropathy and expression of HIF-1α and VEGF in the renal tissues of type 2 diabetic rats. Diabetes Res Clin Pract, 2011, 93, 63-69.
55. Yozai K, Shikata K, Sasaki M, Tone A, Ohga S, Usui H, Okada S et al.: Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions. J Am Soc Nephrol, 2005, 16, 3326-3338. (Pubitemid 46179336)
56. Zafiriou S, Stanner S, Saad S, Polhill T, Poronnik P, Pollock C: Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J Am Soc Nephrol, 2005, 6, 638-645. (Pubitemid 41725100)
57. Zelmanovitz T, Gerchman F, Balthazar A, Thomazelli F, Matos J, Canani L: Diabetic nephropathy. Diabetol Metab Syndr, 2009, 1, 1-10.